"This data is further evidence that our dual-capture chip may be a promising predictive diagnostic tool for cancer patients and their physicians, from early detection of CTCs to the prediction of the success of a specific therapy to real-time monitoring of therapy effectiveness and early detection of recurrence," said Mara G. Aspinall, President and CEO of On-Q-ity. "Our chip is highly unique in this burgeoning field as it is able to capture CTCs via size and affinity, a dual-capture screen that is more precise and effective than either method alone."
On-Q-ity is a next-generation diagnostics company transforming cancer treatment through non-invasive diagnostic monitoring. The company is developing innovative diagnostics to identify the unique characteristics of an individual's cancer, predicting the response to therapy, and monitoring the efficacy of treatment. Headquartered in Waltham, MA, On-Q-ity is funded by Atlas Venture, Bessemer Venture Partners, MDV-Mohr Davidow Ventures, Northgate Capital and Physic Ventures. For more information: www.On-Q-ity.com
CONTACT: Continuum Health Media Contact: Terri Clevenger 203-227-0209 firstname.lastname@example.org